To march in or not to march in

Comment

C Allen Black Jr. Nat Med. 2011.

. 2011 Aug 4;17(8):921; author reply 921-2.

doi: 10.1038/nm.2440.

No abstract available

Comment on

March on, not in.
[No authors listed] [No authors listed] Nat Med. 2011 May;17(5):515. doi: 10.1038/nm0511-515. Nat Med. 2011. PMID: 21546944 No abstract available.

March on, not in.
[No authors listed] [No authors listed] Nat Med. 2011 May;17(5):515. doi: 10.1038/nm0511-515. Nat Med. 2011. PMID: 21546944 No abstract available.
NIH faces marching orders on orphan drug shortage.
Dolgin E. Dolgin E. Nat Med. 2011 May;17(5):522. doi: 10.1038/nm0511-522b. Nat Med. 2011. PMID: 21546953 No abstract available.
[Enzyme therapy in Fabry disease: when scarcity of one enzyme illustrates the vulnerability of biotech].
Lidove O, Choukroun G, Bekri S, Viot G, Tsimaratos M, Joly D. Lidove O, et al. Presse Med. 2010 May;39(5):527-9. doi: 10.1016/j.lpm.2010.01.002. Epub 2010 Mar 2. Presse Med. 2010. PMID: 20194001 French. No abstract available.
Expert opinion on temporary treatment recommendations for Fabry disease during the shortage of enzyme replacement therapy (ERT).
Linthorst GE, Germain DP, Hollak CE, Hughes D, Rolfs A, Wanner C, Mehta A; European Medicines Agency. Linthorst GE, et al. Mol Genet Metab. 2011 Jan;102(1):99-102. doi: 10.1016/j.ymgme.2010.11.155. Epub 2010 Nov 30. Mol Genet Metab. 2011. PMID: 21123099
Enzyme replacement therapy for Fabry disease: lessons from two alpha-galactosidase A orphan products and one FDA approval.
Desnick RJ. Desnick RJ. Expert Opin Biol Ther. 2004 Jul;4(7):1167-76. doi: 10.1517/14712598.4.7.1167. Expert Opin Biol Ther. 2004. PMID: 15268683 Review.

Debates over orphan drug pricing: a meta-narrative literature review.
Hanchard MS. Hanchard MS. Orphanet J Rare Dis. 2025 Mar 7;20(1):107. doi: 10.1186/s13023-025-03634-2. Orphanet J Rare Dis. 2025. PMID: 40055799 Free PMC article. Review.